NASDAQ:RGC Regencell Bioscience (RGC) Stock Price, News & Analysis $12.01 -2.81 (-18.96%) Closing price 04:00 PM EasternExtended Trading$12.18 +0.17 (+1.42%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Regencell Bioscience Stock (NASDAQ:RGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Regencell Bioscience alerts:Sign Up Key Stats Today's Range$11.89▼$14.8550-Day Range$12.01▼$32.2452-Week Range$9.39▼$69.00Volume379,687 shsAverage Volume279,060 shsMarket Capitalization$5.94 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Read More Regencell Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreRGC MarketRank™: Regencell Bioscience scored higher than 8% of companies evaluated by MarketBeat, and ranked 82nd out of 88 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRegencell Bioscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRegencell Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Regencell Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioRegencell Bioscience has a P/B Ratio of 1,202.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.16% of the float of Regencell Bioscience has been sold short.Short Interest Ratio / Days to CoverRegencell Bioscience has a short interest ratio ("days to cover") of 8.44.Change versus previous monthShort interest in Regencell Bioscience has recently decreased by 2.27%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRegencell Bioscience does not currently pay a dividend.Dividend GrowthRegencell Bioscience does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.07 News SentimentRegencell Bioscience has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Regencell Bioscience this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for RGC on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows1 people have added Regencell Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regencell Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Regencell Bioscience is held by insiders.Percentage Held by Institutions0.13% of the stock of Regencell Bioscience is held by institutions.Read more about Regencell Bioscience's insider trading history. Receive RGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regencell Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGC Stock News HeadlinesREGENCELL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGCJune 18 at 1:42 PM | globenewswire.comSueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGCJune 18 at 10:09 AM | prnewswire.comA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a district with over 4 million ounces of historical production. Surrounded by major operators including Coeur Mining and Centerra, the project holds a historical resource estimated at 3.31 million ounces of gold. With funding and permits in place for an active drill program and an updated NI 43-101 resource targeted for 2027, the setup offers multiple near-term catalysts - all against a backdrop of gold near record highs and a structurally short copper market.June 18 at 1:00 AM | Wall Street Logic (Ad)RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud LawsuitJune 17 at 7:56 PM | prnewswire.comREGENCELL DEADLINE TUESDAY JUNE 23rd: Bragar Eagel & Squire, P.C. Reminds Regencell Bioscience Holdings Limited (NASDAQ:RGC) Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff RoleJune 17 at 6:09 PM | globenewswire.comDeadline Alert: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitJune 17 at 1:24 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 17 at 12:00 PM | globenewswire.comRGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Securities Lawsuit - Contact Levi & KorsinskyJune 17 at 10:15 AM | prnewswire.comSee More Headlines RGC Stock Analysis - Frequently Asked Questions How have RGC shares performed this year? Regencell Bioscience's stock was trading at $21.00 at the start of the year. Since then, RGC stock has decreased by 42.8% and is now trading at $12.02. How were Regencell Bioscience's earnings last quarter? Regencell Bioscience Holdings Limited (NASDAQ:RGC) issued its quarterly earnings data on Friday, May, 8th. The company reported ($0.01) earnings per share for the quarter. When did Regencell Bioscience's stock split? Regencell Bioscience shares split on the morning of Monday, June 16th 2025.The 38-1 split was announced on Monday, June 2nd 2025. The newly minted shares were distributed to shareholders after the closing bell on Sunday, June 15th 2025. An investor that had 100 shares of stock prior to the split would have 3,800 shares after the split. When did Regencell Bioscience IPO? Regencell Bioscience (RGC) raised $22 million in an initial public offering on Wednesday, July 14th 2021. The company issued 2,300,000 shares at a price of $8.50-$10.50 per share. Who are Regencell Bioscience's major shareholders? Regencell Bioscience's top institutional shareholders include Bank of America Corp DE and Amundi. How do I buy shares of Regencell Bioscience? Shares of RGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2026Today6/18/2026Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Medicinal Chemicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RGC Previous SymbolNASDAQ:RGC CIK1829667 WebN/A Phone852 2155 0823Fax852-2155-0853Employees10Year Founded2014Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book1,201.00Miscellaneous Outstanding Shares494,490,000Free Float484,599,000Market Cap$5.94 billion OptionableN/A Beta1.65 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RGC) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...Wall Street Logic | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regencell Bioscience Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Regencell Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
